Biologics for the prophylaxis and treatment of COVID-19
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA85475
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$1,511,057.58Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
N/A
Research Location
AustraliaLead Research Institution
Walter and Eliza Hall Institute of Medical ResearchResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Agents for treatments and prevention of COVID-19 infection are urgently needed. Antibodies are widely used to treat several infectious diseases, as well as autoimmune diseases and cancer. Using novel antibody discovery platforms and high-throughput screening approaches, our team of academic and industry partners is uniquely positioned to accelerate the discovery of an effective and safe antibody-based therapy to combat the new pandemic coronavirus.